206 related articles for article (PubMed ID: 36413364)
1. Low-Value Prostate-Specific Antigen Test for Prostate Cancer Screening and Subsequent Health Care Utilization and Spending.
Kim DD; Daly AT; Koethe BC; Fendrick AM; Ollendorf DA; Wong JB; Neumann PJ
JAMA Netw Open; 2022 Nov; 5(11):e2243449. PubMed ID: 36413364
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Care Cascades Following Low-Value Prostate-Specific Antigen Testing Among Veterans Dually Enrolled in the US Veterans Health Administration and Medicare Systems.
Pickering AN; Zhao X; Sileanu FE; Lovelace EZ; Rose L; Schwartz AL; Oakes AH; Hale JA; Schleiden LJ; Gellad WF; Fine MJ; Thorpe CT; Radomski TR
JAMA Netw Open; 2022 Dec; 5(12):e2247180. PubMed ID: 36520431
[TBL] [Abstract][Full Text] [Related]
3. Downstream tests, treatments, and annual direct payments in older men cared for by primary care providers with high or low prostate-specific antigen screening rates using 100 percent Texas U.S. Medicare public insurance claims data: a retrospective cohort study.
Zanwar P; Lin YL; Kuo YF; Goodwin JS
BMC Health Serv Res; 2016 Jan; 16():17. PubMed ID: 26772175
[TBL] [Abstract][Full Text] [Related]
4. Are there regional tendencies toward controversial screening practices? A study of prostate and breast cancer screening in a Medicare population.
Raffin E; Onega T; Bynum J; Austin A; Carmichael D; Bronner K; Goodney P; Hyams ES
Cancer Epidemiol; 2017 Oct; 50(Pt A):68-75. PubMed ID: 28822325
[TBL] [Abstract][Full Text] [Related]
5. Five-year downstream outcomes following prostate-specific antigen screening in older men.
Walter LC; Fung KZ; Kirby KA; Shi Y; Espaldon R; O'Brien S; Freedland SJ; Powell AA; Hoffman RM
JAMA Intern Med; 2013 May; 173(10):866-73. PubMed ID: 23588999
[TBL] [Abstract][Full Text] [Related]
6. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening.
Leapman MS; Wang R; Park H; Yu JB; Sprenkle PC; Cooperberg MR; Gross CP; Ma X
JAMA Oncol; 2022 Jan; 8(1):41-47. PubMed ID: 34762100
[TBL] [Abstract][Full Text] [Related]
7. Low-Value Prostate Cancer Screening Among Older Men Within the Veterans Health Administration.
Radomski TR; Huang Y; Park SY; Sileanu FE; Thorpe CT; Thorpe JM; Fine MJ; Gellad WF
J Am Geriatr Soc; 2019 Sep; 67(9):1922-1927. PubMed ID: 31276198
[TBL] [Abstract][Full Text] [Related]
8. Trends in Low-Value Health Service Use and Spending in the US Medicare Fee-for-Service Program, 2014-2018.
Mafi JN; Reid RO; Baseman LH; Hickey S; Totten M; Agniel D; Fendrick AM; Sarkisian C; Damberg CL
JAMA Netw Open; 2021 Feb; 4(2):e2037328. PubMed ID: 33591365
[TBL] [Abstract][Full Text] [Related]
9. Effect of the 2012 US Preventive Services Task Force Recommendations on Prostate-Specific Antigen Screening in a Medicare Advantage Population.
Zhu Y; Koethe B; Ollendorf DA; Wong JB; Neumann PJ; Kim DD
Med Care; 2022 Dec; 60(12):888-894. PubMed ID: 36038520
[TBL] [Abstract][Full Text] [Related]
10. Costs and Trends in Utilization of Low-value Services Among Older Adults With Commercial Insurance or Medicare Advantage.
Carter EA; Morin PE; Lind KD
Med Care; 2017 Nov; 55(11):931-939. PubMed ID: 28930892
[TBL] [Abstract][Full Text] [Related]
11. Clinician Factors Associated With Prostate-Specific Antigen Screening in Older Veterans With Limited Life Expectancy.
Tang VL; Shi Y; Fung K; Tan J; Espaldon R; Sudore R; Wong ML; Walter LC
JAMA Intern Med; 2016 May; 176(5):654-61. PubMed ID: 27042937
[TBL] [Abstract][Full Text] [Related]
12. Low-Value Prostate-Specific Antigen Screening in Older Males.
Kalavacherla S; Riviere P; Javier-DesLoges J; Banegas MP; McKay RR; Murphy JD; Rose BS
JAMA Netw Open; 2023 Apr; 6(4):e237504. PubMed ID: 37040113
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
14. Association of Prostate-Specific Antigen Screening Rates With Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities.
Bryant AK; Lee KM; Alba PR; Murphy JD; Martinez ME; Natarajan L; Green MD; Dess RT; Anglin-Foote TR; Robison B; DuVall SL; Lynch JA; Rose BS
JAMA Oncol; 2022 Dec; 8(12):1747-1755. PubMed ID: 36279204
[TBL] [Abstract][Full Text] [Related]
15. Influence of repeated prostate-specific antigen screening on treatment pattern in a country with a limited social perception of prostate cancer: Korean national wide observational study.
Ko YH; Kim SW
Investig Clin Urol; 2021 May; 62(3):282-289. PubMed ID: 33834639
[TBL] [Abstract][Full Text] [Related]
16. Decision fatigue in low-value prostate cancer screening.
Hunt TC; Ambrose JP; Haaland B; Kawamoto K; Dechet CB; Lowrance WT; Hanson HA; O'Neil BB
Cancer; 2021 Sep; 127(18):3343-3353. PubMed ID: 34043813
[TBL] [Abstract][Full Text] [Related]
17. Exnovation of Low Value Care: A Decade of Prostate-Specific Antigen Screening Practices.
Bynum J; Passow H; Carmichael D; Skinner J
J Am Geriatr Soc; 2019 Jan; 67(1):29-36. PubMed ID: 30291742
[TBL] [Abstract][Full Text] [Related]
18. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
Tawfik A
Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Prevalence and Cost of Care Cascades After Routine Testing During the Medicare Annual Wellness Visit.
Ganguli I; Lupo C; Mainor AJ; Wang Q; Orav EJ; Rosenthal MB; Sequist TD; Colla CH
JAMA Netw Open; 2020 Dec; 3(12):e2029891. PubMed ID: 33306120
[TBL] [Abstract][Full Text] [Related]
20. Racial and Ethnic Disparities in the Use of Prostate Magnetic Resonance Imaging Following an Elevated Prostate-Specific Antigen Test.
Abashidze N; Stecher C; Rosenkrantz AB; Duszak R; Hughes DR
JAMA Netw Open; 2021 Nov; 4(11):e2132388. PubMed ID: 34748010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
